A modified protein in benign-appearing meningiomas can reveal which are truly benign and which are more dangerous and require more aggressive treatment, researchers have discovered.Read more
NYU Langone Health and its Perlmutter Cancer Center have launched clinical whole genome DNA methylation profiling for patients with brain tumors.
This leading-edge molecular assay utilizes DNA epigenetic signatures and artificial intelligence with machine learning to correctly identify and subtype brain tumors. NYU Langone Health is the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors.
Tulane University senior James Rogers has been charting a course in the name of research since he arrived on campus in the fall of 2016. Rogers’ journey has led him from New Orleans to Bethesda, Md., across the Atlantic to Scotland and, most recently, Switzerland, where he spent the summer as a visiting research scholar in the Brain Tumor Center at the University Hospital Zürich (USZ).Read more
A new study published this week gives insight into how cancer immunotherapies might one day be delivered directly to the brain in order to treat brain tumors.Read more